Form 8-K Krystal Biotech, Inc. For: Dec 23
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update [Seeking Alpha]Seeking Alpha
- Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026GlobeNewswire
- Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung CancerGlobeNewswire
- Krystal Biotech (NASDAQ:KRYS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 11/3/25 - Beat
KRYS
Sec Filings
- 2/9/26 - Form 144
- 1/12/26 - Form 8-K
- 1/8/26 - Form 8-K
- KRYS's page on the SEC website